The exploratory study to determine predictive biomarkers of response to immune checkpoint inhibitors for patients with metastatic urological cancers

The exploratory study to determine predictive biomarkers of response to immune checkpoint inhibitors for patients with metastatic urological cancers - To determine predictive biomarkers of response to ICIs in urological cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038617

Enrollment

190

Registered

2019-12-28

Start date

2020-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urological cancers

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with metastatic urological cancers treated with immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Predictive biomarkers to predict overall survival	—

Countries

Japan

Contacts

Public ContactYoshiaki Yamamoto

Graduate School of Medicine, Yamaguchi University Department of Urology

yoshiy@yamaguchi-u.ac.jp0836-22-2275

Outcome results